1 – 12 of 12
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Development and validation of a patient-reported outcome measure for systemic sclerosis : the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire
(
- Contribution to journal › Article
- 2020
-
Mark
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis
(
- Contribution to journal › Scientific review
- 2018
-
Mark
Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis : The European Scleroderma Observational Study
(
- Contribution to journal › Article
-
Mark
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study
(
- Contribution to journal › Article
- 2017
-
Mark
Treatment outcome in early diffuse cutaneous systemic sclerosis : The European Scleroderma Observational Study (ESOS)
(
- Contribution to journal › Article
-
Mark
Update of EULAR recommendations for the treatment of systemic sclerosis
(
- Contribution to journal › Article
- 2016
-
Mark
Brief Report : IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies
(
- Contribution to journal › Article
- 2015
-
Mark
Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility
(
- Contribution to journal › Article
- 2011
-
Mark
Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy
(
- Contribution to journal › Article
- 2008
-
Mark
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
(
- Contribution to journal › Article
- 2007
-
Mark
Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
(
- Contribution to journal › Article